Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
02-05 February, 2026
Not Confirmed
Not Confirmed
03-05 February, 2026
Paris Packaging WeekParis Packaging Week
Not Confirmed
Not Confirmed
05-06 February, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
SCOPE Summit
Not Confirmed
Contact SupplierSCOPE Summit
Industry Trade Show
Not Confirmed
02-05 February, 2026
Industry Trade Show
Not Confirmed
03-05 February, 2026
Paris Packaging WeekParis Packaging Week
Industry Trade Show
Not Confirmed
05-06 February, 2026
Digital content
NEWS #PharmaBuzz
05 Jan 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-01-05/bioinvent-reports-promising-data-from-ongoing-phase-2a-study-for-bi-1808-with-keytruda-r-pembroliz
18 Dec 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-12-18/bioinvent-to-participate-in-upcoming-investor-conference
08 Dec 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-12-08/bioinvent-presents-impressive-response-data-from-ongoing-phase-2a-trial-of-triple-combination-bi-120
07 Dec 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-12-07/bioinvent-presents-promising-early-phase-2a-bi-1808-monotherapy-data-in-ctcl-at-ash-2025
18 Nov 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-11-18/bioinvent-announces-publication-of-preclinical-and-early-phase-1-data-for-bi-1607-in-her2-positive-a
17 Nov 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-11-17/ema-positive-opinion-for-orphan-drug-designation-to-bioinvents-bi-1808-for-the-treatment-of-cutaneo
Drugs in Development
Details:
XOMA Royalty has purchased the future TAK-079 (mezagitamab), a fully human immunoglobulin IgG1 monoclonal antibody, royalty and milestone interests held by BioInvent.
Lead Product(s): Mezagitamab
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: XOMA
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement May 27, 2025
Lead Product(s) : Mezagitamab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : XOMA
Deal Size : $30.0 million
Deal Type : Agreement
XOMA Acquires Mezagitamab Royalties From BioInvent for Up to $30 Million
Details : XOMA Royalty has purchased the future TAK-079 (mezagitamab), a fully human immunoglobulin IgG1 monoclonal antibody, royalty and milestone interests held by BioInvent.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 27, 2025
Details:
BI-1206, an antibody targeting FcγRIIB, given in combination with rituximab and acalabrutinib is being evaluated in subjects with indolent B-cell non-hodgkin's lymphoma.
Lead Product(s): BI-1206,Acalabrutinib,Rituximab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2025
Lead Product(s) : BI-1206,Acalabrutinib,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioInvent Shares Updated Phase 2a Data of BI-1206 Combo for Lymphoma
Details : BI-1206, an antibody targeting FcγRIIB, given in combination with rituximab and acalabrutinib is being evaluated in subjects with indolent B-cell non-hodgkin's lymphoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 14, 2025
Details:
BI-1808, a first-in-class anti-TNFR2 antibody candidate, which is currently being evaluated for the treatment of patients with T-cell Lymphoma.
Lead Product(s): BI-1808,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2025
Lead Product(s) : BI-1808,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioInvent Receives FDA FTD for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma
Details : BI-1808, a first-in-class anti-TNFR2 antibody candidate, which is currently being evaluated for the treatment of patients with T-cell Lymphoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 29, 2025
Details:
Takeda initiated Phase 3 clinical trial of TAK-079 (mezagitamab), a fully human, anti-CD38 IgG1 monoclonal antibody, identified from BioInvent's proprietary n-CoDeR® antibody library.
Lead Product(s): Mezagitamab
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 08, 2025
Lead Product(s) : Mezagitamab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
BioInvent Receives Milestone Payment as Takeda Moves Mezagitamab into Phase 3
Details : Takeda initiated Phase 3 clinical trial of TAK-079 (mezagitamab), a fully human, anti-CD38 IgG1 monoclonal antibody, identified from BioInvent's proprietary n-CoDeR® antibody library.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 08, 2025
Details:
BI-1808, a first-in-class anti-TNFR2 antibody candidate, which is currently being evaluated for the treatment of patients with T-cell Lymphoma.
Lead Product(s): BI-1808,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : BI-1808,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioInvent gets FDA Orphan Status for BI-1808 in T-cell Lymphoma
Details : BI-1808, a first-in-class anti-TNFR2 antibody candidate, which is currently being evaluated for the treatment of patients with T-cell Lymphoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 20, 2025
Details:
Keytruda (Pembrolizumab) is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Melanoma.
Lead Product(s): Pembrolizumab,BI-1607,Ipilimumab
Therapeutic Area: Oncology Brand Name: Keytruda
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 20, 2025
Lead Product(s) : Pembrolizumab,BI-1607,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Keytruda (Pembrolizumab) is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Melanoma.
Product Name : Keytruda
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 20, 2025
Details:
BI-1206 is a first-in-class fully human mAb that targets FcγRIIB. It is being evaluated in combination with rituximab in patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma.
Lead Product(s): BI-1206,Rituximab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: CASI Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 05, 2024
Lead Product(s) : BI-1206,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : CASI Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
CASI Pharmaceuticals Reports Positive Interim Phase 1 Data for BI-1206 in China
Details : BI-1206 is a first-in-class fully human mAb that targets FcγRIIB. It is being evaluated in combination with rituximab in patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 05, 2024
Details:
BI-1910 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): BI-1910
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 16, 2024
Lead Product(s) : BI-1910
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI-1910 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 16, 2024
Details:
BT-001 is an oncolytic virus generated using Transgene’s Invir.IO® platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which is investigated in combination with KEYTRUDA® (pembrolizumab) for the treatment of solid tumors, including melanoma.
Lead Product(s): BT-001,Adalimumab,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Recipient: Transgene
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2023
Lead Product(s) : BT-001,Adalimumab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Transgene
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BT-001 is an oncolytic virus generated using Transgene’s Invir.IO® platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which is investigated in combination with KEYTRUDA® (pembrolizumab) for the treatment of solid tumors, including ...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 10, 2023
Details:
BT-001 is an oncolytic virus generated using Transgene’s Invir.IO® platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which encode both a Treg-depleting human recombinant anti-CTLA-4 antibody and the human GM-CSF cytokine.
Lead Product(s): BT-001,Adalimumab,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Transgene
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 25, 2023
Lead Product(s) : BT-001,Adalimumab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Transgene
Deal Size : Inapplicable
Deal Type : Inapplicable
BioInvent and Transgene Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors
Details : BT-001 is an oncolytic virus generated using Transgene’s Invir.IO® platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which encode both a Treg-depleting human recombinant anti-CTLA-4 antibody and the human GM-CSF cytokine.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
BioInvent is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of MONOCLONAL ANTIBODY PRODUCTION bulk offered by BioInvent
Share 
